Altimmune to Participate in the Citizens Life Sciences Conference

GlobeNewswire

Yesterday

Altimmune logo.png

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:

Conference:	Citizens Life Sciences Conference
Date/Time:	Wednesday, May 7, 2025, at 9:30 a.m. EDT

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
Jason.spark@canalecomm.com

This press release was published by a CLEAR® Verified individual.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531035763"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531035763\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531035763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 19:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2531035763","market":"us","top_or_hot":-1,"title":"Altimmune to Participate in the Citizens Life Sciences Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/.RvPvvOJIdYQphH9gg6d9w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009\" title=\"Altimmune logo.png\" vspace=\"5\"/>\n<p>GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:<br/></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Conference:</strong></td>\n<td>Citizens Life Sciences Conference</td>\n</tr>\n<tr>\n<td><strong>Date/Time:</strong></td>\n<td>Wednesday, May 7, 2025, at 9:30 a.m. EDT</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.</p>\n<p><strong>About Altimmune<br/></strong>Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.</p>\n<p><strong>Follow @Altimmune, Inc. on </strong><strong>LinkedIn</strong><br/><strong>Follow @AltimmuneInc on </strong><strong>Twitter</strong><br/></p>\n<p><strong>Company Contact:</strong><br/>Greg Weaver<br/>Chief Financial Officer<br/>Phone: 240-654-1450<br/>ir@altimmune.com<br/><br/><br/><br/></p>\n<p><strong>Investor Contact:</strong><br/>Lee Roth<br/>Burns McClellan<br/>Phone: 646-382-3403<br/>lroth@burnsmc.com<br/><br/><br/><br/></p>\n<p><strong>Media Contact:</strong><br/>Jason Spark<br/>Inizio Evoke, Biotech<br/>Phone: 619-849-6005<br/>Jason.spark@canalecomm.com<br/><br/><br/><br/></p>\n<p>This press release was published by a CLEAR® Verified individual.</p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune to Participate in the Citizens Life Sciences Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune to Participate in the Citizens Life Sciences Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-30 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/altimmune-participate-citizens-life-sciences-113000648.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...</p>\n\n<a href=\"https://finance.yahoo.com/news/altimmune-participate-citizens-life-sciences-113000648.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1878469433.USD","symbol_name":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/altimmune-participate-citizens-life-sciences-113000648.html","article_id":"2531035763","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531035763","pubTimestamp":1746012600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter. This press release was published by a CLEAR Verified individual.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4599":"减肥药","BK4139":"生物科技","ALT":"Altimmune, Inc."},"translate_title":"Altimmune将参加公民生命科学会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:\n\n\n\nConference:\nCitizens Life Sciences Conference\n\n\nDate/Time:\nWednesday, May 7, 2025, at 9:30 a.m. EDT\n\n\n \n \n\n\n\nThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website.\nAbout AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.\nFollow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter\nCompany Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com\nInvestor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com\nMedia Contact:Jason SparkInizio Evoke, BiotechPhone: 619-849-6005Jason.spark@canalecomm.com\nThis press release was published by a CLEAR® Verified individual.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}